IRF3 and melanoma: Although the number of persons with mutated tumors that could be analyzed was limiting the statistical power, the fraction of non-responders or individuals with stable disease upon administration of immune-checkpoint therapy was 19% higher in individuals with melanoma tumors with non-coding mutations in the BCL2L12/IRF3 promoter as compared to individuals without such mutations (Figure 3J).